Zacks.com on MSN15h
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
Cencora Enjoys Growth Momentum From GLP-1s, Healthy Utilization Trends, and Growing Specialty Assets
Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...
Medicine Buffalo11h
Ophthalmic complications in patients on antidiabetic GLP-1 medications are concerning neuro-ophthalmologists
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...